• Username (E-mail)
  • Password
Dow 19,913 0.6%  EStoxx50 3,282 0.3%  Nikkei 18,788 -0.6%  EUR 1.0734 -0.3% 
Nasdaq 5,601 0.9%  FTSE100 7,150 0.0%  Yen 113.7880 1.0%  Oil 55.3 -0.1% 
S&P500 2,280 0.7%  DAX 11,595 0.4%  GBP 1.2516 -0.1%  Gold 1,210 -0.8% 

Vertex Pharmaceuticals share [Symbol: VRTX / ISIN: US92532F1003]

08/01/2012 09:25:44 AM
08/01/2012 09:25:44 AM UTC-0400

Vertex Pharmaceuticals Inc. Neutral

The analysts of Piper Jaffray & Co. have rated Vertex Pharmaceuticals with a Neutral rating. The price target was set to 57.00 $. At a current price of the Vertex Pharmaceuticals stock of 82.24 $ this means a downside potential of -30.69%.
Summary: Vertex Pharmaceuticals Inc. Neutral
Company:
Vertex Pharmaceuticals Inc.
Analyst:
Piper Jaffray & Co.
Price Target:
57.00 $
Current Rating:
Neutral
Price*:
49.17 $
Distance to Target Price*:
15.94%
Previous Rating:
Downgrade
Latest Price:
82.24 $
Distance Price Target:
-30.69%
Analyst Name::
Edward A. Tenthoff
P/E Ratio*:
-

Analyst Opinions for Vertex Pharmaceuticals Inc.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
12/14/12
Vertex Pharmaceuticals Goldman Sachs Group Inc.
12/05/12
Vertex Pharmaceuticals RBC Capital Markets
11/13/12
Vertex Pharmaceuticals Credit Suisse Group
11/05/12
Vertex Pharmaceuticals Goldman Sachs Group Inc.
11/02/12
Vertex Pharmaceuticals UBS AG

Add or Edit Instrument

Related Stocks

Latest Analyst Opinions
01/23/17 TLG IMMOBILIEN Norddeutsche Landesbank (Nord/LB)
01/23/17 ABB JP Morgan Chase & Co.
01/23/17 Zurich Insurance Group JP Morgan Chase & Co.
01/23/17 Apple Bernstein Research
01/23/17 Novo Nordisk A-S (B) JP Morgan Chase & Co.
01/23/17 Sky UBS AG
01/23/17 Vodafone Group UBS AG
01/23/17 BT Group UBS AG
01/23/17 RHÖN-KLINIKUM Independent Research GmbH
01/23/17 Credit Suisse Morgan Stanley
01/23/17 Deutsche Bank Morgan Stanley
01/23/17 Intesa Sanpaolo JP Morgan Chase & Co.
01/23/17 HORNBACH Baumarkt Hauck & Aufhäuser Privatbankiers KGaA
01/23/17 RHÖN-KLINIKUM Commerzbank AG
01/23/17 NORMA Group Oddo Seydler Bank AG
01/23/17 Reckitt Benckiser Group Barclays Capital
01/23/17 Deutsche Bank Commerzbank AG
01/23/17 LOréal Barclays Capital
01/23/17 Diageo Barclays Capital
01/23/17 LVMH Moet Hennessy Louis Vuitton Deutsche Bank AG
01/23/17 Renault UBS AG
01/23/17 Continental UBS AG
01/23/17 Daimler UBS AG
01/23/17 adidas Deutsche Bank AG
01/23/17 AstraZeneca Deutsche Bank AG
01/23/17 CompuGroup Medical Baader Bank
01/23/17 Bechtle Baader Bank
01/23/17 Beiersdorf Barclays Capital
01/23/17 Henkel vz Barclays Capital
01/23/17 Unilever Barclays Capital
01/23/17 Unilever Barclays Capital
01/23/17 GlaxoSmithKline Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
01/23/17 Orange Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
01/23/17 BNP Paribas Deutsche Bank AG
01/23/17 Société Générale SA Deutsche Bank AG
01/23/17 zooplus Warburg Research
01/23/17 ASML Baader Bank
01/23/17 Novo Nordisk A-S (B) Kepler Cheuvreux
01/23/17 Vonovia Kepler Cheuvreux
01/23/17 AIXTRON Baader Bank
01/23/17 Anheuser-Busch InBev UBS AG
01/23/17 PUMA Deutsche Bank AG
01/23/17 Glencore UBS AG
01/23/17 BT Group UBS AG
01/23/17 Royal Dutch Shell (A) UBS AG
01/23/17 Eni UBS AG
01/23/17 LOréal UBS AG
01/23/17 PUMA JP Morgan Chase & Co.
01/23/17 Novo Nordisk A-S (B) Goldman Sachs Group Inc.
01/23/17 Hapag-Lloyd Aktiengesellschaft Goldman Sachs Group Inc.